Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Down 6.52%
As of Thursday, November 12, Anavex Life Sciences Corp.’s AVXL share price has dipped by 6.52%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company’s ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Commentary & Analysis
Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Down 5.33%
As of Tuesday, November 10, Anavex Life Sciences Corp.’s AVXL share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Tudor Pop
Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Up 8.70%
As of Monday, November 09, Anavex Life Sciences Corp.’s AVXL share price has surged by 8.70%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Down 11.10%
As of Thursday, November 05, Anavex Life Sciences Corp.’s AVXL share price has dipped by 11.10%, which has investors questioning if this is right time to buy.Michael Rose
Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Up 7.46%
As of Tuesday, November 03, Anavex Life Sciences Corp.’s AVXL share price has surged by 7.46%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | AVXL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $91.7 | $218.8 | 22% |
|
| Shares Out (Mil) | 92.9 | 55.0 | 60% |
|
| Institutional Ownership | 92.7% | 92.8% | 62% |
|
| Float (Mil) | 89.8 | 42.0 | 58% |
|
| Beta | 1.14 | 0.96 | 67% |
|
| Avg Daily Volume (000s) | 1,045 | 546 | 68% |
|
| Price Change (52-week) |
(85.6%) | 44.0% | 7% |
|
| Growth | AVXL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (12.0%) | (10.3%) | 27% |
|
| EPS (5yr) | (3.8%) | 15.8% | 27 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (37.5%) | (15.7%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AVXL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $41 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($43) | 27% |
|
| EPS (TTM) | ($0.145) | ($1.500) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($29) | ($35) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $106 | $157 | 22% |
|
| Valuation | AVXL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.82 | 2.08 | 20% |
|
| P/E | na | 17.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AVXL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.1% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (11.7%) | (47.4%) | 24% |
|
| ROE | (12.8%) | (52.5%) | 26% |
|
| Liabilities to Assets | 6.4% | 29.7% | 3% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 11/12/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 2.6% |
| +/- S&P 500: | -4.8 |
